203 related articles for article (PubMed ID: 16437697)
21. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.
Jin X; Wu Y
Afr Health Sci; 2015 Mar; 15(1):123-30. PubMed ID: 25834540
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
24. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.
Kuhlmann KF; van Till JW; Boermeester MA; de Reuver PR; Tzvetanova ID; Offerhaus GJ; Ten Kate FJ; Busch OR; van Gulik TM; Gouma DJ; Crawford HC
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):886-91. PubMed ID: 17507610
[TBL] [Abstract][Full Text] [Related]
26. Application values of detection of serum CA199, CA242 and CA50 in the diagnosis of pancreatic cancer.
Lei XF; Jia SZ; Ye J; Qiao YL; Zhao GM; Li XH; Chang H
J Biol Regul Homeost Agents; 2017; 31(2):383-388. PubMed ID: 28685541
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
Sun Y; Duan Q; Wang S; Zeng Y; Wu R
J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
[TBL] [Abstract][Full Text] [Related]
29. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
30. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
31. Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer.
Fujimoto Y; Suehiro Y; Kaino S; Suenaga S; Tsuyama T; Matsui H; Higaki S; Fujii I; Suzuki C; Hoshida T; Matsumoto T; Takami T; Nagano H; Sakaida I; Yamasaki T
Oncology; 2021; 99(4):234-239. PubMed ID: 33440396
[TBL] [Abstract][Full Text] [Related]
32. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
Robles-Diáz G; Aceves G; Galván E
Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
[TBL] [Abstract][Full Text] [Related]
33. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
34. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma].
Pei DP
Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060
[TBL] [Abstract][Full Text] [Related]
35. Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.
Ching CK; Rhodes JM
Br J Cancer; 1989 Jun; 59(6):949-53. PubMed ID: 2736232
[TBL] [Abstract][Full Text] [Related]
36. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
37. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
38. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
39. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]